- Home
- NXGL vs EQ Comparison
NXGL vs EQ Comparison
Compare NXGL & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXGL
- EQ
- Stock Information
- Founded
- NXGL 1997
- EQ 2017
- Country
- NXGL United States
- EQ United States
- Employees
- NXGL N/A
- EQ N/A
- Industry
- NXGL Medical/Dental Instruments
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- NXGL Health Care
- EQ Health Care
- Exchange
- NXGL Nasdaq
- EQ Nasdaq
- Market Cap
- NXGL 23.8M
- EQ 24.8M
- IPO Year
- NXGL 2021
- EQ 2018
- Fundamental
- Price
- NXGL $3.28
- EQ $0.63
- Analyst Decision
- NXGL
- EQ Buy
- Analyst Count
- NXGL 0
- EQ 2
- Target Price
- NXGL N/A
- EQ $5.00
- AVG Volume (30 Days)
- NXGL 121.9K
- EQ 130.9K
- Earning Date
- NXGL 11-13-2024
- EQ 11-13-2024
- Dividend Yield
- NXGL N/A
- EQ N/A
- EPS Growth
- NXGL N/A
- EQ N/A
- EPS
- NXGL N/A
- EQ N/A
- Revenue
- NXGL $6,729,000.00
- EQ $45,914,000.00
- Revenue This Year
- NXGL $120.47
- EQ $4.76
- Revenue Next Year
- NXGL $38.19
- EQ N/A
- P/E Ratio
- NXGL N/A
- EQ N/A
- Revenue Growth
- NXGL 90.57
- EQ 7.70
- 52 Week Low
- NXGL $1.84
- EQ $0.49
- 52 Week High
- NXGL $5.10
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- NXGL 38.55
- EQ 37.33
- Support Level
- NXGL $3.27
- EQ $0.49
- Resistance Level
- NXGL $3.93
- EQ $0.73
- Average True Range (ATR)
- NXGL 0.38
- EQ 0.08
- MACD
- NXGL -0.09
- EQ -0.01
- Stochastic Oscillator
- NXGL 11.02
- EQ 38.92
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating, and cross-linking technologies.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.